ABSTRACT
More recently, Cross et al. evaluated a polyvalent E. coli vaccine in humans (157). Based on the fact that a limited number of 0 serogroups account for nearly 70% of bacteremic and meningitic E. coli isolates. the vaccine was prepared by formulation of conjugates of 0 polysaccharides coupled to exotoxin A that represented 12 serogroups of E. coli (01, 02. 04, 06-08, 012, 015. 016, 018, 025, and 075). Fourfold or greater increases in ELISA antibody levels over baseline were greatest ( > 60% of vaccines) for 01 , 02, 06-08, and 015; intermediate (-50%) for 018 and 075; and poorest (~45%) for 04, 012, 016, and 025. Opsonic antibody titers generally paralleled ELISA antibody responses. In addition to the potential use for active immunization, this E. coli vaccine would ultimately be combined with existing Klebsiella and Pseudomonas vaccines in order that a broadly protective, multispecitic hyperimmune IVIG(EC/PA/KP HYPERIVIG) might be produced (139-141,144).
